PHILADELPHIA--(BUSINESS WIRE)-- Rite Aid Corporation (NYSE: RAD) (“Rite Aid” or the “Company”) today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Company to accelerate its ongoing business transformation. Implementing the contemplated restructuring plan will significantly reduce the Company’s debt, increase its financial flexibility and enable it to execute on key initiatives. In connection with this, Rite Aid has initiated a voluntary court-supervised process under Chapter 1...
PHILADELPHIA--(BUSINESS WIRE)-- Rite Aid Corporation (NYSE: RAD) (“Rite Aid” or the “Company”) today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth (“Busy”) Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company’s Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Ste...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The independent financial analyst theScreener just lowered the general evaluation of RITE AID (US), active in the Drug Retailers industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date January 21, 2022, the closing price was USD 10.56 and its target price was ...
Rating Action: Moody's upgrades Rite Aid's CFR to B3. Global Credit Research- 30 Sep 2021. New York, September 30, 2021-- Moody's Investors Service today upgraded Rite Aid Corporation's Corporate Family Rating to B3 from Caa1 and it probability of default rating to B3-PD from Caa1-PD.
The market is expecting STZ to see the fundamental momentum the company has built the past decade between a shift to a premiumization strategy and the move into beer to reveres due to the pandemic. The market expects the company, which has seen UAFRS-based (Uniform) ROA improve from 10% levels to almost 30% to decline to the low end of levels since its Grupo Modelo acquisition, not recognizing the company's strong business model that is unlikely to be disrupted. Constellation's strong pro...
Rite Aid Corporation (RAD:USA) currently trades at a discount to Uniform assets, with a 0.9x Uniform P/B. At these levels, the market is pricing in expectations for profitability to remain muted, and management may have concerns about realizing Elixir's potential, continued wage inflation, and the recovery of the acute business. Specifically, management may lack confidence in their ability to sustain Q1 results, maintain market share growth, and continue their current pace of vaccine administr...
Rating Action: Moody's changes Rite Aid's outlook to positive; affirms Caa1 CFR. Global Credit Research- 13 May 2021. New York, May 13, 2021-- Moody's Investors Service, today changed the outlook for Rite Aid Corporation to positive from stable.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Rite Aid Corporation. Global Credit Research- 23 Mar 2021. New York, March 23, 2021-- Moody's Investors Service has completed a periodic review of the ratings of Rite Aid Corporation and other ratings that are associated with the same analytical unit.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Current market expectations for II-VI Incorporated (IIVI) don't comprehend the company's macro tailwinds. Markets expect UAFRS-based (Uniform) ROA (ROA') to fall back towards historical trough levels, even as analysts are forecasting significant ROA' recovery, in line with the tailwinds from its exposure to 5G investment, the Internet of Things, and autonomous vehicle investment. The company supplies the technology that allows these big macro tailwinds to continue to take off, and in the case o...
Rite Aid Corporation (RAD:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 24.3x Uniform P/E. At these levels, the market has bullish expectations for the firm, but management may have concerns about their omnichannel capabilities, store remodeling costs, and weak flu and cold volumes Specifically, management may lack confidence in their ability to mitigate drug cost-driven adjusted EBITDA declines, sustain retail pharmacy market share gains, and...
CBRL has been steadily improving UAFRS-based (Uniform) ROA the past 10 years, thanks to its strong strategy to optimize its restaurant and store business. While the market is pricing the company for returns post-pandemic to decline to multi-year lows absent 2020,the company's strategy primes them for ROA expansion. The company's resiliency through the pandemic, combined with its ability to accelerate growth with its decision to roll-out alcohol puts it in place to see significant return expansi...
Rite Aid Corporation (RAD:USA) currently trades at a discount relative to UAFRS-based (Uniform) assets, with a 0.9x Uniform P/B. At these levels, the market has bullish expectations for the firm, but management may have concerns about their expenses for safety and cleanliness, revenue growth, and RediClinics demand Specifically, management may lack confidence in their ability to become a market leader in mid-market pharmacy benefit management (PBM), and they may be concerned about additional ex...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.